At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 42 target
Drug / intervention
MR001 Bispecific Antibody for Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/IIa, Open-Label, Two-Cohort, Dose-Escalation and Dose-Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) Who Have Progressed After First-Line or Later-Line Therapy
In Brief
A Phase 2 clinical trial evaluating MR001 Bispecific Antibody for Injection for Triple-Negative Breast Cancer (TNBC). Currently recruiting, targeting 42 participants across 1 site.
Detailed Summary
This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 in patients with advanced triple-negative breast cancer (TNBC) who have progressed after prior therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriple-Negative Breast Cancer (TNBC)
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
202620272028
First PostedOct 2025
Enrollment StartJan 2026
TodayJul 2026
Primary CompletionSep 2028
First PostedOct 6, 2025
Enrollment StartJan 29, 2026
Primary CompletionSep 1, 2028
TodayJul 1, 2026
Enrollment to primary: 2.6 yearsPosted 9 months agoPrimary completion in 2.2 years
Interventions
MR001 Bispecific Antibody for Injectiondrug
Intravenous infusion